Optimizing immunosuppressive therapy after renal transplantation
Year: 2015
Type: dissertation
Abstract: Non-immune donor risksDeceased donor kidney, donation after circulatory death Donor age above 60 years, female donor sex, donor vascular disease or vascular comorbidity Ischaemia-reperfusion injury and long ischaemia times Delayed graft function Non-immune recipient risks and causes Female sex, size mismatch, obesity Ascending urinary tract infection and graft pyelonephritis Transplant ureteric obstruction Polyoma (BK) virus nephropathy Calcineurin inhibitor nephrotoxicity Recurrent renal disease or de novo glomerulonephritis Hypertension, hyperlipidaemia, smoking, proteinuria Pre-existing or post-transplantation diabetes Alloimmune factors Child or adolescent recipient Ethnicity with altered disposition of immunosuppressive agents Variable concentration of medication Recipient's genetic trait for alloimmune and inflammatory response Histoincompatibility, recipient presensitisation, and pre-existent donor specific antibodies Acute rejection that is severe, steroid-resistant, vascular, antibodymediated, or occurring late after transplantation Subclinical rejection, chronic T-cell mediated rejection, late de novo anti-HLA antibody formation, chronic antibody-mediated rejection with transplant glomerulopathy Non-adherence to immunosuppressive drugs CorticosteroidsCorticosteroids are used in renal transplantation as induction and maintenance therapy and to treat acute rejections.Corticosteroids act by binding to the glucocorticoid receptor and this complex subsequently binds to the nuclear DNA where it regulates the expression of genes that control the immune response and inflammation (4).The use of corticosteroids is associated with a broad range of toxicities like skin fragility, bodyweight gain, osteoporosis, hypertension, dyslipidaemia, and hyperglycaemia (4).of mycophenolate mofetil.Rheumatology.
Author: Gerben A.J. van Boekel
Language: English
Subfield: Transplantation
Field: Medicine
Domain: Health Sciences
Keywords: kidney transplantation, immunosuppressive therapy, calcineurin inhibitors, corticosteroids, mycophenolate mofetil, acute rejection, BK virus nephropathy, ischemia-reperfusion injury, donor risk factors, recipient risk factors, drug toxicity, immunosuppression adherence, antibody-mediated rejection, transplant glomerulopathy
Open Access status: green
Funder: Astellas Pharma
OpenAlex ID: W1126265774
